Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03727698

Acronym

PERMIT

Enrollment

200

Registered

2018-11-01

Start date

2019-01-11

Completion date

2025-11-30

Last updated

2019-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

The purpose of PERMIT is to collect information on the treatment of radiotherapy patients using a new radiotherapy machine that includes magnetic Resonance (MR) imaging (MR linac) to guide treatment. The aim is to use this information to support the introduction of MR Linac into clinical practice. PERMIT will collect details on patients treated on the MR linac plus details on their side effects and other outcomes. This information plus technical and imaging information will be combined with information from other centres using this machine. By doing so this will help us learn how best to use the MR Linac in the future and design new radiotherapy protocols

Interventions

DEVICEMR Linac

MR guided radiotherapy treatment

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

To assess delivery of radiotherapy on the MR Linac for multiple tumour sites

Eligibility

Sex/Gender

ALL

Age

5 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Radiotherapy treatment suitable to be delivered on the MR Linac. 2. Patient provides written, informed consent and/or authorization. 3. Patients between the ages of 5 and under 16 years old may enter protocol with parental/guardian consent.

Exclusion criteria

1. Contra-indications to MR imaging. 2. Radiotherapy not suitable for delivery on the MR Linac e.g. those with extended field lengths (exceeding 20 cm).

Design outcomes

Primary

Measure	Time frame	Description
Technical feasibility of undertaking MRL based radiotherapy at multiple clinical sites: The percentage of treatment fractions delivered successfully on the MR linac	2 years	The percentage of treatment fractions delivered successfully on the MR linac, if more than 20 % of patients (depending on treatment site) need to be treated on alternative machine or treatment protocol changed will lead to the MRL protocol at that site to be judged not feasible.

Countries

United Kingdom

Contacts

Primary ContactRobert Huddart

robert.huddart@icr.ac.uk44 208 661 3425

Backup ContactLorna Bower, BSc

lorna.bower@icr.ac.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026